Gene: HILPDA
Official Full Name: hypoxia inducible lipid droplet associatedprovided by HGNC
Gene Summary: Enables signaling receptor binding activity. Involved in several processes, including autocrine signaling; cellular response to hypoxia; and positive regulation of lipid storage. Located in several cellular components, including cell surface; lipid droplet; and secretory granule. Implicated in colorectal cancer and hepatocellular carcinoma. Biomarker of colorectal cancer and hepatocellular carcinoma. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO26940 | HILPDA Knockout cell line (HeLa) | Human | HILPDA | 1:3~1:6 | Negative | Online Inquiry |
KO26941 | HILPDA Knockout cell line (HCT 116) | Human | HILPDA | 1:2~1:4 | Negative | Online Inquiry |
KO26942 | HILPDA Knockout cell line (HEK293) | Human | HILPDA | 1:3~1:6 | Negative | Online Inquiry |
KO26943 | HILPDA Knockout cell line (A549) | Human | HILPDA | 1:3~1:4 | Negative | Online Inquiry |
HILPDA Gene Knockout Cell Lines represent a crucial advancement in genetic research, allowing scientists to study the function of the HILPDA gene in various biological processes. These cell lines are specifically engineered to have a complete knockout of the HILPDA gene, which encodes for a protein implicated in lipid metabolism and inflammatory responses. By removing this gene, researchers can create a controlled environment to explore the physiological and pathophysiological characteristics associated with altered expressions of HILPDA and its impact on cellular signaling pathways.
The key function of these knockout cell lines lies in their ability to provide insights into the role of HILPDA in disease models, including its potential implications in metabolic disorders, cancer, and inflammatory diseases. The absence of HILPDA allows for the observation of compensatory mechanisms within cells and how these alterations can lead to various phenotypic outcomes. This provides a powerful tool for researchers studying gene function, signaling pathways, and treatment targets.
Scientifically, HILPDA Gene Knockout Cell Lines are invaluable in both basic and applied research settings. They facilitate the validation of drug targets and biomarkers for disease treatment while also serving as preclinical models to evaluate therapeutic strategies. Compared to traditional methods such as transient transfection or CRISPR-Cas9 gene editing, these stable cell lines offer a consistent genetic background, eliminating variability and enhancing reproducibility in experimental results.
The specific advantages of utilizing HILPDA Gene Knockout Cell Lines include their availability for high-throughput screening applications and the capability to combine them with other molecular techniques, such as gene expression analysis or metabolomics. This makes them an essential resource for both academic researchers and pharmaceutical companies focused on drug discovery and development.
Investing in HILPDA Gene Knockout Cell Lines provides researchers and clinicians with a robust tool to uncover new biological insights and translate these findings into innovative therapies. With our extensive expertise in developing cutting-edge biological products, we are committed to supporting scientific advancement through high-quality, reliable research tools tailored to the needs of the scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.